ERBB2 and neoplasm: When the antitumor effect of the TRAB to HER2 was examined in a human CD3 EDG–replaced mouse model engrafted with Hepa1-6/hGPC3/HER2 cells, the antitumor effect was significant, with 149% tumor growth inhibition (TGI, calculated by equation (2) in the Methods section) at 28 days after tumor implantation (Fig. 10A).